Omada: 3 Key Takeaways for Long-Term Investors
· fool.com · popularity 17/100 · 0 similar stories today · Breaking & World News (World News & Media)
Read the original at fool.com →
Summary
Omada's cost to serve fell to an all-time low, and it has seemingly found a way to profit from GLP-1 drugs whether employers pay for them or not. On …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 15.